1 / 14

Medication: Past, Present, and Future in Racing and Performance Horses

Medication: Past, Present, and Future in Racing and Performance Horses. Scot Waterman, DVM Executive Director. Racing Medication & Testing Consortium. Began in 2001 at a facilitated meeting hosted by the AAEP to assess whether uniform medication rules were achievable

lenore
Download Presentation

Medication: Past, Present, and Future in Racing and Performance Horses

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Medication: Past, Present, and Future in Racing and Performance Horses Scot Waterman, DVM Executive Director

  2. Racing Medication & Testing Consortium • Began in 2001 at a facilitated meeting hosted by the AAEP to assess whether uniform medication rules were achievable • RMTC Goals: uniform rules, standardized testing, available money for research, improved security, information resource for racing commissions • Incorporated as a 501 c (3)

  3. AAEP AQHA Arabian Jockey Club California TB Trainers Churchill Downs Del Mar Hambletonian Society Harness Tracks of America The Jockey Club      Jockeys’ Guild Keeneland KTA Magna Entertainment National HBPA NTRA NYRA Oak Tree RCI THA TOBA TB Owners of California TRA TRPB USTA Board of Directors

  4. Racing Medication & Testing Consortium • Diverse, large Board can be difficult but it ensures that no single agenda can drive the development of a rule, supermajority required for language to pass • Standard approach is to divide work up into sub-committees and bring the consensus back to the full Board • Language is either adopted by the Board, edited and then approved or sent back to the sub-committee

  5. Board members Rick Arthur (Oak Tree) Nancy Goodman (AQHA) Ted Hill (The Jockey Club) Bobby Lewis (AAEP) Gregg Scoggins (MEC) Ex officio Glenn Blodgett (AQHA) Ron Jensen (Advisor) Milton McLure (AAEP) Wayne McIlwraith (AAEP) Committees Tom Brokken Gary Norwood Dan Wilson Tom Tobin Mike Weber Veterinarian involvement in the RMTC

  6. Model Rules Phase 1 (2005) • Prohibited Practices • Drug Classifications/Categorization • Permitted Therapeutics: • Voluntary use of furosemide with post-race regulatory control • One of three NSAIDs – Bute, Banamine or Ketoprofen – at 24 hours • Adopted now by 32/38 racing jurisdictions

  7. Uniform Penalties (2006) • Three-tiered grid system simplified existing RCI penalties • Significantly increases penalties for illegal and prohibited performance-enhancing drugs • Reduces penalties for therapeutic medication mistakes • Redefines trainer responsibility • Mitigating and aggravating circumstances “checklist” for stewards • Added penalties for other culpable licensees: veterinarians, owners and grooms • Adopted as rule or policy in 25 states

  8. Model Rules Phase 3 (2007) • Regulation of anabolic steroids • Thresholds for four FDA-permitted or endogenous anabolics • Stanozolol • Boldenone • Nandrolone • Testosterone • 30-45 days withdrawal time • Out-of-competition testing • Blood-doping agents – EPO & Darbypoietin • Illegal & prohibited drugs

  9. Model Rules-Present & FutureWithdrawal Times Research • Identify drugs with legitimate uses • Prioritize drugs into five groups • Collect previous science on each drug • If science is insufficient then perform administrations on a minimum of 20 horses • Plasma is preferred but some drugs will have both urine and plasma collected • Ultimate goal…uniform withdrawal time with a corresponding concentration of drug which regulates the withdrawal time

  10. Priority Group 1 Acepromazine Butorphanol Detomidine Glycopyrrolate Lidocaine Mepivacaine Methocarbamol Pyrilamine Priority Group 2 Boldenone Dantrolene Dexamethasone Firocoxib Fluphenazine Hydroxyzine Nandrolone Stanozolol Testosterone Withdrawal Times Research

  11. Priority Group 3 Albuterol Betamethasone Diclofenac Methylprednisolone Reserpine Triamcinolone Trichlormethiazide Xylazine Priority Group 4 Atropine Beclomethasone Buscopan Cromolyn Isoxsuprine Pentoxyfylline Phenytoin Prednisolone Withdrawal Times Research

  12. Model Rules-Present & Future Withdrawal Time Database • Withdrawal times posted for 18 jurisdictions and over 70 drugs • Database is searchable by drug and by jurisdiction • Over 2,000 unique users in first month of availability • www.rmtcnet.com, click on “Withdrawal Times” tab at top of page

  13. RMTC-Present & FutureDrug Testing Initiatives • Develop strategies to improve drug testing in US: • Integrate WADA laboratory standards • Overhaul of Laboratory Quality Assurance Programs • Development of a post-doctoral recruitment program • Development of a business plan for U.S. drug testing infrastructure which includes research and development laboratory

  14. Big picture…the future • Beginning to see organizations with “sticks” use them to drive change: • Thoroughbred Owners and Breeders Association Graded Stakes Committee • Breeder’s Cup • NTRA Safety Alliance • The Jockey Club Safety Committee • Hambletonian Society

More Related